322 results on '"Holdenrieder, Stefan"'
Search Results
52. Auf dem Weg zur multimodalen Nukleinsäurediagnostik im Blutplasma.
53. Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
54. Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization
55. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies
56. German Society for Clinical Chemistry and Laboratory Medicine – areas of expertise: Division reports from the German Congress of Laboratory Medicine 2022 in Mannheim, 13–14 October 2022
57. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19.
58. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
59. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
60. A pocket companion to cell-free DNA (cfDNA) preanalytics.
61. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update.
62. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.
63. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
64. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
65. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients.
66. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology
67. zlog-NT-proBNP bei Kindern mit angeborenen Herzfehlern
68. Cell-Free DNA in Plasma and Serum Indicates Disease Severity and Prognosis in Blunt Trauma Patients
69. High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon
70. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
71. RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
72. De Ritis ratio and long‐term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention
73. Measurement of Platelet Aggregation in Ageing Samples and After in-Vitro Activation
74. Prognostic value of De Ritis ratio with aspartate aminotransferase and alanine aminotransferase within the reference range
75. The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
76. A zlog-based algorithm and tool for plausibility checks of reference intervals
77. Isolation and Quantification of Plasma Cell-Free DNA Using Different Manual and Automated Methods
78. NT‐proBNP and Zlog‐transformed NT‐proBNP values predict extubation failure in critically ill neonates with pulmonary hypertension and ventricular dysfunction
79. COVID-19 Infections in Adults with Congenital Heart Disease—A Prospective Single-Center Study in an Outpatient Setting
80. Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
81. Prognostic value of De Ritis ratio in patients with acute myocardial infarction
82. Understanding the use of evidence in the WHO Classification of Tumours: a protocol for an evidence gap map of the classification of tumours of the lung
83. High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
84. New Perspectives on the Importance of Cell-Free DNA Biology
85. Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients
86. Cell-Free DNA Fragmentation Patterns in a Cancer Cell Line
87. Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease
88. Auf die Datenaufbereitung kommt es an.
89. Cell-Free Nucleic Acids: Physico-Chemical Properties, Analytical Considerations, and Clinical Applications.
90. Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures
91. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
92. CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia
93. Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer
94. The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies
95. The potential of extracellular microRNAs as diagnostic biomarkers for acute pulmonary infections
96. The potential of extracellular microRNAs as diagnostic biomarkers for acute pulmonary infections
97. A zlog-based algorithm and tool for plausibility checks of reference intervals.
98. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study
99. Increased N-terminal Pro-B-Type Natriuretic Peptide during Extracorporeal Life Support Is Associated with Poor Outcome in Neonates with Congenital Diaphragmatic Hernia
100. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.